Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal fluticasone for adenotonsillar hypertrophy in children
IRCT20210228050524N1Phase 2Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluticasone in Adenotonsillar hypertrophy (ATH), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Change in rhinorrhea, Change in snoring and 2 more. Started Mar 2021; status: completed.
02
Drugs
fluticasone
03
Conditions
Adenotonsillar hypertrophy (ATH)
Beyond the preview
Go deeper on IRCT20210228050524N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210228050524N1.